From JPMA Vision" for Japan after the experience of the new type of Corona
What kind of "vision" will be needed to connect the social security system to the next generation and for the pharmaceutical industry to contribute to health and the economy--?
On this theme, we had a discussion with Dr. Manami Hori, Dean of Tokai University's School of Health Sciences. Mr. Masaki Kawasaki, Senior Manager of the Japan Research Institute, served as moderator for the discussion, which covered various aspects of what the pharmaceutical industry should aim for.
The content of the discussion was published in the Shakaihoken Junpo (Social Insurance Journal), so please take a look at it.
Click here to read the full article.
https://www.jpma.or.jp/news_room/movie_ad/magazine/#vision-ad
(From May 11, 2022, Shakaihoken Junpo No.2855)
Japan Pharmaceutical Manufacturers Association, Inc.
Yasushi Okada, Chairman
Japan Pharmaceutical Manufacturers Association (JPMA)
Japan Pharmaceutical Manufacturers Association (JPMA)
Founded in 1968, the Pharmaceutical Manufacturers Association of Japan (PMAJ) is a voluntary association of R&D-oriented pharmaceutical companies that has contributed to global healthcare through the development of innovative new ethical drugs under the motto "Realization of Patient Participatory Medicine".
The Pharmaceutical Manufacturers Association of Japan (PMAJ) is engaged in a multifaceted program of activities to solve various problems common to the pharmaceutical industry, to deepen understanding of pharmaceuticals, and to promote international collaboration. In addition, we are committed to the sound development of the pharmaceutical industry, particularly by strengthening our policy formulation and advocacy activities, addressing internationalization, and reinforcing our public relations system.
Aiming to contribute to society through the development of new drugs Japan Pharmaceutical Manufacturers Association (JPMA)